Skip to main content
Publications
Melen E, Faner R, Allinson JP, Bui D, Bush A, Custovic A, Garcia-Aymerich J, Guerra S, Breyer-Kohansal R, Hallberg J, Lahousse L, Martinez FD, Merid SK, Powell P, Pinnock H, Stanojevic S, Vanfleteren LEGW, Wang G, Dharmage SC, Wedzicha J, Agusti Alvar, Abellan A , CADSET Investigators. Lung-function trajectories: relevance and implementation in clinical practice . Lancet. 2024 Apr 13;403(10435):1494-503. doi: 10.1016/S0140-6736(24)00016-3
Reed SD, Zhou X , Ichikawa L, Gatz JL, Peipert JF, Armstrong MA, Raine-Bennett T, Getahun D, Fassett MJ, Postlethwaite DA, Shi JM, Asiimwe A, Pisa F, Schoendorf J, Saltus CW , Anthony MS , APEX-IUD study team. Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study . Lancet. 2022 Jun 4;399(10341):2103-12. doi: 10.1016/S0140-6736(22)00015-0
Ko DT, Khan AM , Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study . J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Fine P, Victora CG, Rothman KJ , Moore PS, Chang Y, Curtis V, Heymann DL, Slutkin G, May RM, Patel V, Roberts I, Wortley R, Torgerson C, Deaton A. John Snow's legacy: epidemiology without borders . Lancet. 2013 Apr 1;381(9874):1302-11.
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S , Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary . Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A , Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors . Clin Cancer Res. 2003 Jun 1;9(6):2040-8.